Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles.
Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University.[1] Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky.[1][when?] He was also on the faculty of the University of California, Davis.[2][when?] From 2013 to 2015, he was the Chief Scientific Officer of Aethlon Medical's wholly owned subsidiary, Exosome Sciences.[3][4]
Taylor first described exosomes in the 1980s, originally believing them to be cell fragments.[5] He later wrote that exosomes could potentially be used as biomarkers for profiling in ovarian cancer biopsies, and could extend their utility to screening other asymptomatic areas.[6] What constitutes exosomes has not been defined; specifically, markers of exosomes do not exist.[7]
In 2015, the Journal of Immunology retracted a paper it published in 2006 and which Taylor had co-written[8] after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified".[9][10] Taylor responded to the retraction on the blog Retraction Watch, disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred".[10]
References edit
- ^ a b "Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board". PR Newswire (Press release). Retrieved August 31, 2016.
- ^ UC Davis Health System, Department of Public Affairs and Marketing. "UC Davis Health System Feature Story: Cancer in the crosshairs". ucdavis.edu. Retrieved 15 July 2015.
- ^ "Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc". PR Newswire (Press release). Retrieved August 31, 2016.
- ^ "Executive Team". Exosome Sciences. Archived from the original on August 17, 2015. Retrieved March 3, 2016.
- ^ Todd S. Ing, et al, Dialysis: History, Development and Promise (Hackensack, New Jersey: World Scientific Publishing, 2012), p. 843
- ^ Taylor, Douglas (July 2008). "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer". Gynecologic Oncology. 110 (1): 13–21. doi:10.1016/j.ygyno.2008.04.033. PMID 18589210.
- ^ Edgar, James (2016). "Q&A: What are exosomes, exactly?". BMC Biology. 14 (1): 46. doi:10.1186/s12915-016-0268-z. PMC 4906597. PMID 27296830.
- ^ Taylor, DD; Akyol, S; Gercel-Taylor, C (2006). "Pregnancy-associated exosomes and their modulation of T cell signaling". J Immunol. 176 (3): 1534–42. doi:10.4049/jimmunol.176.3.1534. PMID 16424182.
- ^ "Retraction: Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling," Journal of Immunology, June 15, 2015, vol. 194 no. 12 6190.(subscription required)
- ^ a b Bernès, Sylvain (June 10, 2015). "Exosome pioneer's paper retracted after investigation finds "multiple" faked figures". Retraction Watch. Retrieved January 7, 2016.